Genelux (NASDAQ:GNLX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Genelux (NASDAQ:GNLX) from a hold rating to a sell rating in a report released on Sunday morning.

GNLX has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Loop Capital set a $16.00 price target on Genelux in a research report on Tuesday, October 21st. HC Wainwright restated a “buy” rating on shares of Genelux in a report on Monday, January 5th. Lake Street Capital assumed coverage on shares of Genelux in a report on Tuesday, October 21st. They set a “buy” rating and a $16.00 target price for the company. Finally, Maxim Group set a $20.00 target price on shares of Genelux in a research report on Tuesday, October 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Genelux Stock Up 3.4%

Genelux stock opened at $2.74 on Friday. The business’s 50-day moving average price is $4.61 and its 200 day moving average price is $4.38. Genelux has a 52 week low of $1.99 and a 52 week high of $8.53. The firm has a market cap of $104.26 million, a price-to-earnings ratio of -3.11 and a beta of 0.17.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Equities analysts expect that Genelux will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other news, Director John Thomas sold 10,000 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.00, for a total transaction of $50,000.00. Following the completion of the transaction, the director directly owned 492,784 shares in the company, valued at approximately $2,463,920. This represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 15,990 shares of company stock valued at $82,054 in the last ninety days. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Genelux

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new stake in shares of Genelux during the 1st quarter valued at approximately $239,000. Flputnam Investment Management Co. increased its stake in Genelux by 708.1% in the 3rd quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock valued at $1,261,000 after purchasing an additional 263,131 shares in the last quarter. Woodward Diversified Capital LLC raised its holdings in Genelux by 21.7% during the second quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock worth $5,104,000 after purchasing an additional 317,173 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Genelux during the second quarter worth $656,000. Finally, MAI Capital Management grew its holdings in Genelux by 66,161.3% in the second quarter. MAI Capital Management now owns 236,553 shares of the company’s stock valued at $679,000 after purchasing an additional 236,196 shares during the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.